Revelation Biosciences Inc is an innovative biotechnology company dedicated to developing breakthrough therapeutic solutions for respiratory diseases, including allergies and asthma. By leveraging its proprietary research platform, the firm is committed to addressing significant unmet medical needs through its advanced R&D initiatives. With a promising pipeline of therapies and strategic collaborations within the industry, Revelation is well-positioned to navigate regulatory challenges and enhance patient outcomes, aiming to deliver substantial therapeutic advancements for those affected by respiratory conditions.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-10.04M |
| Operating Margin | 0.00% |
| Return on Equity | -124.40% |
| Return on Assets | -66.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.32 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $3.44M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on REVBW and any ticker you trade — then tracks every position and per-strategy win rate.